2023 World Conference on Lung Cancer (Posters)-P2.05. Full Spectrum Flow Cytometry-powered Analysis of PBMC as Biomarkers for Immunotherapy in NSCLC with EGFR-TKI Resistance

P2.05. Full Spectrum Flow Cytometry-powered Analysis of PBMC as Biomarkers for Immunotherapy in NSCLC with EGFR-TKI Resistance - PDF(Slides)

Back to course

Pdf Summary

A study was conducted to explore the effectiveness of immune checkpoint inhibitors (ICI) in combination with chemotherapy for non-small cell lung cancer (NSCLC) patients who had previously failed EGFR-TKI treatment. The study enrolled 60 patients who received the combination treatment, of which 24 had blood samples collected before and after two cycles of treatment. Full spectrum flow cytometry was used to analyze the peripheral blood mononuclear cells (PBMCs) for biomarkers related to immunotherapy.<br /><br />The study found that patients with higher levels of effective CD4T cells at baseline had a higher proportion of clinical benefits from the combination treatment. Additionally, higher expression of immune checkpoint proteins (ICPs) like CD25 on dendritic cells and central memory CD8T cells were also associated with better efficacy. After two cycles of treatment, higher expression of CD25 on CD8T/EM8/NK cells was correlated with better efficacy.<br /><br />On the other hand, dynamic changes in the expression of ICPs were related to worse efficacy. The study found a significant decrease in TIGIT expression on regulatory T cells (Treg) and a decrease in VISTA expression on Th1 cells in patients with worse efficacy.<br /><br />A prediction model for the efficacy of ICI plus chemotherapy was successfully constructed, with a sensitivity of 62.5% and specificity of 100%. The model had an area under the curve (AUC) of 0.817, indicating its potential to predict response to the treatment.<br /><br />Overall, the study revealed that the expression levels of ICPs on immune cells, particularly CD25, were significantly correlated with the efficacy of immunotherapy. These findings highlight the importance of robust efficacy biomarkers for immunotherapy in NSCLC patients who have failed EGFR-TKI treatment.

Asset Subtitle

Chunxia Su

Meta Tag

Speaker Chunxia Su

Topic Metastatic NSCLC: Immunotherapy - Biomarker

Keywords

immune checkpoint inhibitors

chemotherapy

non-small cell lung cancer

EGFR-TKI treatment

CD4T cells

biomarkers

flow cytometry

ICPs

TIGIT expression

VISTA expression